Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
41-60 of 991 trials

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Heart Attack Recovery: Milvexian Study

We are testing a new oral medication, milvexian, to see if it helps reduce the risk of further heart problems in patients after a heart attack. This study compares milvexian to a placebo alongside standard treatment.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

NonAdvanced Systemic Mastocytosis: Bezuclastinib Study

We are testing a new oral medication, bezuclastinib, to see if it is effective and safe for patients with NonAdvanced Systemic Mastocytosis. This study compares the medication to a placebo to understand its potential benefits.

Systemic Mastocytosis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Dexamethasone for Moderate to Severe Depression

We are studying whether adding dexamethasone to standard depression treatment can improve symptoms for those with moderate to severe depression. This trial aims to assess its safety and effectiveness.

Depression6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Multiple Myeloma: Iberdomide vs. Lenalidomide Maintenance Therapy

We are comparing two treatments for newly diagnosed multiple myeloma patients after stem cell transplant to see which one may help keep the disease from worsening. This study will also look at safety and quality of life for participants.

Newly Diagnosed Multiple Myeloma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Atopic Dermatitis: Rocatinlimab Study

We are investigating the long-term safety and effectiveness of rocatinlimab for adults and adolescents with moderate-to-severe atopic dermatitis. The study compares the treatment's effects to a placebo in those who have previously responded to the medication.

Atopic DermatitisConfirmation phase (III)Investigational MedicinesCost ReimbursementAllergologyDermatology

Ovarian Cancer: Mirvetuximab Soravtansine with Bevacizumab

We are studying a new treatment combining mirvetuximab soravtansine and bevacizumab for adults with recurrent ovarian cancer who have not progressed after chemotherapy. The goal is to see if this combination helps patients live longer without their cancer worsening.

Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Itacitinib: Continued Treatment Study

We are providing ongoing treatment for participants who have benefited from itacitinib in earlier studies. This study aims to evaluate the safety of continued use of this medication.

Chronic Graft Versus Host DiseaseBronchiolitis Obliterans SyndromeMyelofibrosisEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicineOncology

Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

Advanced CancerAutoimmune Hemolytic AnemiaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Major Depressive Disorder: Minocycline vs. Celecoxib

We are studying whether minocycline or celecoxib can help patients with Major Depressive Disorder who haven't responded to previous treatments. The trial will compare how well these medications work and how patients respond to them.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPsychiatry

Chronic Lymphocytic Leukemia: Nemtabrutinib Study

We are comparing a new treatment called nemtabrutinib to standard options for patients with untreated chronic lymphocytic leukemia. The study aims to find out which treatment works better and is safer.

Small Lymphocytic Lymphoma (SLL) / Chronic Lymphocytic Leukemia (CLL)6-12 monthsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Leukemia and Lymphoma: Ruxolitinib and Venetoclax Study

We are studying the safety and effectiveness of ruxolitinib and venetoclax in children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. This research aims to find better treatment options for these young patients.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Acute Ischemic Stroke: Redasemtide Study

We are investigating whether redasemtide can improve recovery in adults who have had an acute ischemic stroke. Participants will receive either the medication or a placebo to compare effects.

Ischaemic Stroke>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Asthma in Children: QMF149 vs. Budesonide

We are studying whether QMF149 can improve lung function and reduce asthma symptoms in children aged 6 to under 12 compared to Budesonide. This trial will help us understand which treatment works better for young patients.

Asthma6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018

We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.

Fallopian Tube CancerPrimary Peritoneal CancerOvarian CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Roxadustat for Anemia in Children with Chronic Kidney Disease

We are studying a new treatment for anemia in children and adolescents with chronic kidney disease. The trial will evaluate its effectiveness, safety, and how it impacts daily life.

Nephrogenic Anemia1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyNephrology

H3 K27M-Mutant Diffuse Glioma: ONC201 Treatment Study

We are studying the effects of ONC201 in patients with H3 K27M-mutant diffuse glioma after radiotherapy. The goal is to see if it improves outcomes compared to a placebo.

H3 K27M-Mutant Diffuse GliomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology